Please assess the completion status of the following clinical trial:

Trial Title: Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years old~* Admitted for acute decompensated HF with left ventricular ejection fraction (LVEF) \<40%~* Refractory fluid overload:~* Unresponsive (\<500 mL net negative over previous 24 hours) AND ineffective diuresis (determined by HF team) to moderate intensity push or low intensity continuous infusion loop diuretic (80 mg IV furosemide or equivalent bumetanide dose of 4 mg)~* English or Spanish-speaking subjects~* Willing and able to comply with study procedures~Exclusion Criteria:~* Baseline thiazide use prior to admission or prior to study enrollment~* Renal replacement therapies (RRT) or glomerular filtration rate (GFR) \<30 mL/min at the time of enrollment~* Pregnant women~* Cognitive impairment~* Prisoners~* Left ventricular assist devices (LVAD) or temporary mechanical circulatory support devices~* History of cardiac transplant~* Reported allergy to thiazides~* No enteral access or unable to take medications enterally~* Palliative diuretics~* Systolic blood pressure (SBP) \<90 mm Hg prior to randomization~* Patients receiving concomitant lithium therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metolazone (Type: ACTIVE_COMPARATOR): Metolazone 5 mg by mouth once daily for 2 days
- Chlorothiazide (Type: ACTIVE_COMPARATOR): Chlorothiazide 500 mg IV once daily for 2 days

Based on this trial design, predict the completion outcome and termination type (if applicable).